Decades ago, psoriasis was viewed as a skin disease. However, recent evidence has shown that it is a systemic inflammatory disease. This activity will discuss the pathophysiology of psoriasis and its associated comorbidities and psychosocial consequences, capitalizing on the need for effective systemic therapy.
In this Clinical Coffee Break, Dr. Jacob Levitt reviews the different presentations of plaque psoriasis and compares the various therapy classes, including topical corticosteroids, conventional systemic therapies, and biologics. He also discusses how to select treatments based on symptom severity, and which treatments to avoid in special populations, such as pregnant women and those with renal insufficiency.
Although it is now clear that psoriasis is a systemic disease with associated comorbidities, many primary care physicians continue to treat it with local agents. This case study will review when patients with psoriasis should be treated with topical therapy, when to refer patients to specialists for treatment with systemic agents, what prerequisite work-up is needed prior to the initiation of biologics/immunosuppression, and how to monitor patients with psoriasis on biologic therapy for potential safety and efficacy issues.
The primary goal of this multi-faceted educational program is to improve the PCP’s ability to recognize the signs and symptoms of psoriatic disease, when to refer to specialty, and how to collaboratively advance patients along the correct treatment pathway in order to improve patient health outcomes.
Although it is now clear that psoriasis is a systemic disease with associated comorbidities, many primary care physicians continue to treat moderate-to-severe psoriasis with local agents. In this activity, Anthony P. Fernandez, MD, PhD, answers questions submitted by participants during the Virtual Expert Roundtable titled "Optimizing Diagnosis and Management of Psoriatic Disease in Primary Care."